PL2013236T3 - Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK - Google Patents

Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK

Info

Publication number
PL2013236T3
PL2013236T3 PL07720099T PL07720099T PL2013236T3 PL 2013236 T3 PL2013236 T3 PL 2013236T3 PL 07720099 T PL07720099 T PL 07720099T PL 07720099 T PL07720099 T PL 07720099T PL 2013236 T3 PL2013236 T3 PL 2013236T3
Authority
PL
Poland
Prior art keywords
antibodies
bind
tyrosine kinase
extracellular domain
kinase receptor
Prior art date
Application number
PL07720099T
Other languages
English (en)
Inventor
Der Maur Adrian Auf
Peter Lichtlen
Alcide Barberis
Original Assignee
Delenex Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics Ag filed Critical Delenex Therapeutics Ag
Publication of PL2013236T3 publication Critical patent/PL2013236T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07720099T 2006-04-28 2007-04-27 Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK PL2013236T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79583106P 2006-04-28 2006-04-28
EP07720099.6A EP2013236B1 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
PCT/CH2007/000202 WO2007124610A1 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Publications (1)

Publication Number Publication Date
PL2013236T3 true PL2013236T3 (pl) 2015-12-31

Family

ID=38515389

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07720099T PL2013236T3 (pl) 2006-04-28 2007-04-27 Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK

Country Status (16)

Country Link
US (3) US7902340B2 (pl)
EP (2) EP2013236B1 (pl)
JP (2) JP5431920B2 (pl)
KR (1) KR101457228B1 (pl)
CN (1) CN101443361B (pl)
AU (1) AU2007246144B2 (pl)
BR (1) BRPI0710971A2 (pl)
CA (1) CA2650822C (pl)
DK (1) DK2013236T3 (pl)
ES (1) ES2547248T3 (pl)
IL (1) IL194752A0 (pl)
MX (1) MX2008013705A (pl)
NZ (1) NZ572248A (pl)
PL (1) PL2013236T3 (pl)
RU (1) RU2460540C2 (pl)
WO (1) WO2007124610A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008013705A (es) * 2006-04-28 2008-11-06 Esbatech Ag Anticuerpos que se enlazan al dominio extracelular de la cinasa de linfoma anaplastico del receptor tirosina cinasa.
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
LT3444274T (lt) 2008-06-25 2021-03-25 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys tnf
BRPI0914663A2 (pt) 2008-06-25 2015-10-20 Esbatech Alcon Biomed Res Unit humanização de anticorpos de coelho usando uma estrutura de anticorpo universal
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
ES2861435T3 (es) 2011-11-03 2021-10-06 Univ Pennsylvania Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
CN104861069B (zh) * 2014-02-21 2018-12-18 无锡傲锐东源生物科技有限公司 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
US20170100428A1 (en) * 2014-05-30 2017-04-13 Kolltan Pharmaceuticals, Inc. Regulators of anaplastic lymphoma kinase and uses thereof
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
SG11201803054UA (en) * 2015-10-13 2018-05-30 Eureka Therapeutics Inc Antibody agents specific for human cd19 and uses thereof
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
WO2017147408A1 (en) * 2016-02-25 2017-08-31 The Regents Of The University Of California Methods for the treatment of hematologic cancer
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
JP7654402B2 (ja) * 2018-02-09 2025-04-01 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN113960313B (zh) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21505A (en) * 1858-09-14 Improvement in bullet-machines
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
JPH1116250A (ja) * 1997-06-20 1999-01-22 Pioneer Electron Corp 情報再生システム
ATE273323T1 (de) * 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
EP1305337B1 (en) * 2000-06-14 2010-03-10 Georgetown University Pleiotrophin growth factor receptor alk for the treatment of proliferative, vascular and neurological disorders
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
JP2006508638A (ja) * 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
CA2579764A1 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
MX2008013705A (es) * 2006-04-28 2008-11-06 Esbatech Ag Anticuerpos que se enlazan al dominio extracelular de la cinasa de linfoma anaplastico del receptor tirosina cinasa.

Also Published As

Publication number Publication date
DK2013236T3 (en) 2015-09-21
US20150203829A1 (en) 2015-07-23
US20110159008A1 (en) 2011-06-30
US20080118512A1 (en) 2008-05-22
BRPI0710971A2 (pt) 2011-05-31
RU2008146922A (ru) 2010-06-10
EP2013236B1 (en) 2015-06-17
KR101457228B1 (ko) 2014-11-04
EP2604627A1 (en) 2013-06-19
JP5911821B2 (ja) 2016-04-27
JP2013226144A (ja) 2013-11-07
CN101443361B (zh) 2015-08-19
EP2013236A1 (en) 2009-01-14
US9512411B2 (en) 2016-12-06
ES2547248T3 (es) 2015-10-02
CN101443361A (zh) 2009-05-27
CA2650822C (en) 2017-03-14
AU2007246144B2 (en) 2012-12-06
KR20080113261A (ko) 2008-12-29
RU2460540C2 (ru) 2012-09-10
CA2650822A1 (en) 2007-11-08
AU2007246144A1 (en) 2007-11-08
US7902340B2 (en) 2011-03-08
MX2008013705A (es) 2008-11-06
WO2007124610A1 (en) 2007-11-08
HK1124619A1 (en) 2009-07-17
JP5431920B2 (ja) 2014-03-05
US8945563B2 (en) 2015-02-03
NZ572248A (en) 2011-08-26
JP2009535021A (ja) 2009-10-01
IL194752A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
PL2013236T3 (pl) Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK
HUS2100050I1 (hu) IL-6 receptor elleni javított antitest molekula
LTC2379594I2 (lt) Žmogaus CGRP receptorių rišantys antikūnai
BRPI0922224A2 (pt) composições de inibidores de proteína tirosina quiinase receptora.
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
LTPA2018002I1 (lt) Didelio afiniškumo žmogaus antikūnai prieš žmogaus IK-4 receptorius
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
EP2004654A4 (en) Kinase Antagonists
DK2358746T3 (da) Bindingsproteiner til inhibering af vegf-a-receptorinteraktionen
BRPI0820407A2 (pt) Uso de anticorpos anti-cd40
RU2458924C3 (ru) Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
EP2244575A4 (en) Angiotensin-II Receptor Antagonists
ES2411907T8 (es) Uso terapéutico de anticuerpos antirreceptor TWEAK
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
EP2348846A4 (en) DISUBSTITUTED AZEPANOREXINE RECEPTOR ANTAGONISTS
MX2010005031A (es) Anticuerpos de axl.
EP2206775A4 (en) ANTI-IL-6 receptor antibody
DK2081951T3 (da) Progesteron-receptorantagonister
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
DK2155838T3 (da) Fremgangsmåde til fremstilling af forgrenede carbonhydrider
BRPI0923359A2 (pt) Anticorpos anti-igf
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
BRPI0809931A2 (pt) Antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo